Latest Capricor Therapeutics News & Updates

See the latest news and media coverage for Capricor. We track all announcements, press releases, and industry mentions in real time, all in one place.

Capricor Therapeutics (Capricor)

Biotechnology company developing cell and exosome-based therapeutics

capricor.com

Headquarters: San Diego, United States
Founded year: 2005
Company type: Public company
Number of employees: 50–300
Industry: Pharmaceuticals

Last updated Today

Latest news about Capricor Therapeutics (Capricor)

In short: Capricor faced an FDA panel rejection for its Duchenne therapy, leading to a review extension to 2026 and several securities lawsuits.

Company announcements

August 13 Capricor

Capricor reports Q2 2026 financial results and Deramiocel update

Cash at $238M, net loss widened to $40.7M, FDA advisory committee voted against, but HOPE-3 published in The Lancet.

July 29 Capricor

Capricor announces publication of HOPE-3 data in The Lancet

The peer-reviewed results show a 54% slowing of upper limb decline and cardiac benefit in Duchenne patients.

July 27 Capricor

Capricor provides update on FDA advisory meeting for Deramiocel

Capricor responds to FDA briefing materials, highlighting HOPE-3 trial results and statistical plan differences ahead of the July 29 advisory committee meeting.

June 26 Capricor

Capricor announces FDA advisory committee meeting for Deramiocel

The meeting is on July 29, 2026, and the PDUFA date is August 22, 2026.

Media coverage

September 14 Investing.com

B.Riley upgrades Capricor Therapeutics stock rating ahead of FDA date By Investing.com

Investing.com - B.Riley upgraded Capricor Therapeutics (NASDAQ:CAPR) to Buy from Neutral on Monday and raised its price target to $21 from $5.

September 13 Yahoo Finance

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions...

September 3 L'Observateur

Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data...

Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License...

September 1 Yahoo Finance

Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision

Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target t...

Never miss news about Capricor

Track Capricor and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Capricor competitors & trending companies

Browse news for competitors to Capricor and other trending companies.